Waverley Pharma has blamed deep discounting and heavy competition for its decision to step back from generics and focus entirely on novel drug development.

Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Having made its entry into the UK oncology generics market late last year with capecitabine and temozolomide, Canada’s Waverley Pharma now has clearance to add erlotinib tablets to its portfolio.